Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regentis Biomaterials Ltd. Ordinary Shares (NY:RGNT)

1.980 -0.080 (-3.88%)
Streaming Delayed Price Updated: 9:50 AM EDT, Jul 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regentis Biomaterials Ltd. Ordinary Shares

< Previous 1 2 Next >
Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives Japan Patent Allowance for GelrinC Manufacturing Technology
Via Investor Brand Network
Topics Intellectual Property
News headline image
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
From Regentis Biomaterials Ltd
Via ACCESS Newswire
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process
Via Investor Brand Network
News headline image
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
From Regentis Biomaterials Ltd
Via ACCESS Newswire
The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics
Via Investor Brand Network
News headline image
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
From Regentis Biomaterials Ltd
Via ACCESS Newswire
Top movers analysis in the middle of the day on 2026-06-16: top gainers and losers in today's session. ↗
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
Discover the most active stocks in Monday's session. ↗
Via Chartmill
Unusual volume stocks are being observed in Monday's session. ↗
Via Chartmill
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Sphere 3D Corp. (NASDAQ: ANY): Why Its 53MW Power Platform Is Drawing Attention Beyond Bitcoin Mining
Via AB Newswire
Topics Artificial Intelligence Economy
Top stock movements in today's session. ↗
Via Chartmill
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
Tuesday's session: top gainers and losers ↗
Via Chartmill
Which stocks are most active on Tuesday? ↗
Via Chartmill
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
Get insights into the top gainers and losers of Tuesday's pre-market session. ↗
Via Chartmill
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances European Commercial Launch Plans for GelrinC
Via Investor Brand Network
News headline image
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate
Via ACCESS Newswire
News headline image
Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones
Via Investor Brand Network
BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) Is ‘One to Watch’
Via Investor Brand Network
Regentis Biomaterials Ltd. (NYSE American: RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair
Via Investor Brand Network
News headline image
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
Via ACCESS Newswire
News headline image
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
Via ACCESS Newswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.